Latest research
Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.
Top papers this month · This week's roundup
Trending topics
In two phase 3 trials in moderate-to-severe hidradenitis suppurativa, secukinumab every 2 weeks improved week-16 clinical response vs placebo (45% vs 34%; 42% vs 31%); every 4 weeks was significant only in SUNRISE (46% vs 31%), not SUNSHINE (42% vs 34%).
RCTn = 1,084
Kimball et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials